Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Unoprostone Isopropyl

FDA-approved product (solution/drops, ophthalmic), marketed as Rescula.

Registered studies
3
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Unoprostone Isopropyl
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Unoprostone Isopropyl. Its therapeutic class is shown instead.

WHO therapeutic group
Prostaglandin analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

3registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Unoprostone Isopropyl in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Unoprostone Isopropyl with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

    NCT07074782 · start 2026-05

    Registered record
    Registry ID
    NCT07074782
    Conditions
    Glaucoma
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2026-06
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa

    NCT01786395 · start 2013-03

    Registered record
    Registry ID
    NCT01786395
    Conditions
    Retinitis Pigmentosa
    Interventions
    UF-021; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-03
    Completion
    Not recorded
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinitis Pigmentosa
    InterventionUF-021; Placebo
    PhasePhase 3
    Registry statusTerminated

  • A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration

    NCT01379560 · start 2011-05

    Registered record
    Registry ID
    NCT01379560
    Conditions
    Dry Age-related Macular Degeneration
    Interventions
    unoprostone isopropyl; unoprostone isopropyl
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2011-12
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Age-related Macular Degeneration
    Interventionunoprostone isopropyl; unoprostone isopropyl
    PhasePhase 2
    Registry statusCompleted